Abstracts Archive - Page 268 of 2607 - ACR Meeting Abstracts

Abstract Number: 0497 • ACR Convergence 2024
Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
Adrián Quevedo-Rodríguez¹, Marta Hernández-Díaz², Dara Rodríguez-González2², Fuensanta Gomez-Bernal³, Juan Carlos Quevedo-Abeledo⁴, Agustín F González-Rivero², Elena González López⁵, gonzalo Ocejo-Viñals⁵, Miguel Angel Gonzalez-Gay⁶ and ivan Ferraz-Amaro⁷, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁵Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0578 • ACR Convergence 2024
Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
Muhammad Saeed¹, HIna Ahmed² and Aziza Ahmed³, and Arthritis Carte Foundation Faculty, ¹Central Park Medical College, Arthritis Care Foundation, Lahore, Pakistan, ²Central Park Medical College, Lahore, Pakistan, ³Rashid Latif Medical College, Lahore, Pakistan
Background/Purpose: In patients with Axial Spondyloarthritis (axSpA) there has been wide variability in terms of gender regarding disease characteristics as well as outcomes across different…
Abstract Number: 0588 • ACR Convergence 2024
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Laura Coates¹, Carlo Selmi², Philip Mease³, Alexis Ogdie⁴, Francois Nantel⁵, Frederic Lavie⁶, Mohamed Sharaf⁷, Oyediran Adelakun⁸, Emmanouil Rampakakis⁹, Laura Pina Vegas¹⁰ and Lihi Eder¹¹, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Nantel MedSci Consult, Montreal, QC, Canada, ⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁷Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁸Janssen Research & Development, LLC, Titusville, NJ, ⁹McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 0559 • ACR Convergence 2024
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Diego Benavent¹, Victor Fanjul², Sytske Anne Bergstra³, Floris van Gaalen⁴, Maxime Dougados⁵, Umut Kalyoncu⁶, Denis Poddubnyy⁷, Clementina López Medina⁸, Konstantinos Parperis⁹, David Vega-Morales¹⁰, Desiree van der Heijde¹¹ and Victoria Navarro Compán¹², ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²Savana Research, Madrid, ³LUMC, Leiden, Netherlands, ⁴LUMC, Leiden, Zuid-Holland, Netherlands, ⁵Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁶Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁷Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁸Reina Sofia University Hospital, Cordoba, Spain, ⁹University of Cyprus Medical School, Nicosia, Cyprus, ¹⁰Instituto Mexicano del Seguro Social, Monterrey, México, Monterrey, Mexico, ¹¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…
Abstract Number: 0587 • ACR Convergence 2024
Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
William Tillett¹, Dafna Gladman², Laure Gossec³, Jason Eells⁴, Patrick Healy⁵, Barbara Ink⁴, Nikos Lyris⁴ and Jessica A Walsh⁶, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Sorbonne Université, Paris, France, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Morrisville, NC, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) negatively impacts patients’ physical health and functional ability, which can contribute to reduced work productivity.1,2 We examined the association between achieving…
Abstract Number: 0571 • ACR Convergence 2024
Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
Sabrina Hamroun¹, Laure Gossec², Serge Perrot³, Maxime Dougados⁴ and Anna Molto⁵, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Sorbonne Université, Paris, France, ³Paris Dauphine University, Paris, France, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: There are several tools for assessing disease activity in spondyloarthritis (SpA). The literature reveals gender differences, with unfavorable Patient Reported Outcomes in women compared…
Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Maureen Dubreuil¹, Marina Magrey², Kathrin Haeffs³, Evgueni Ivanov⁴ and Julie Gandrup Horan⁵, ¹Section of Rheumatology, Boston University School of Medicine, Boston, MA, ²Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Bulle, Switzerland, ⁵UCB Pharma, Slough, United Kingdom
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0567 • ACR Convergence 2024
Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
Pankaj Sharma¹, Fatemeh Navid¹, Norman Watts¹, Stephen Brooks² and Robert Colbert², ¹National Institutes of Health, Bethesda, MD, ²NIH/NIAMS, Bethesda, MD
Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
Abstract Number: 0598 • ACR Convergence 2024
Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Eva van Geel¹, Romy Hansildaar², Fatih Çoban¹, Bas Dijkshoorn¹, Maaike Heslinga¹, Reinhard Bos³, Mies Korteweg¹, Arno Van Kuijk¹ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular disease. Studies have suggested that treatment with apremilast is associated with weight loss and other…
Abstract Number: 0540 • ACR Convergence 2024
Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
Jose Meade Aguilar¹, Jean Liew², Rachael Stovall³, Sofia Ramiro⁴ and Lianne S Gensler⁵, ¹Boston Medical Center, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³University of Washington, Seattle, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…
Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Elena Zholobova³, Elizaveta Krekhova⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sofia Kuzkina⁶, Mikhail Samsonov⁶, Irina Nikishina⁷ and Mikhail Kostik⁵, ¹National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²National Medical Research Center of Children's Health, Moscow, Russia, ³Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁴National Medical Research Centre for Children's Health, Moscow, Russia, ⁵Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁶R-Pharm, Moscow, Russia, ⁷V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].